OncoMatch/Clinical Trials/NCT07164313
A Study of ZW251 in Participants With Advanced Solid Tumors
Is NCT07164313 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies ZW251 for hepatocellular carcinoma.
Treatment: ZW251 — The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Non-Small Cell Lung Carcinoma
Testicular Germ Cell Tumor
Performance status
ECOG 0–1(Restricted strenuous activity)
ECOG Performance Status score of 0 or 1
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function; acute or chronic uncontrolled renal disease excluded
Liver function
Liver function status of Child-Pugh Class A (for HCC only)
Adequate organ function; Liver function status of Child-Pugh Class A (for HCC only)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCSF Comprehensive Cancer Center · San Francisco, California
- University of California Los Angeles - Cancer Care - Santa Monica (UCLA) · Santa Monica, California
- Norton Cancer Institute · Louisville, Kentucky
- START Midwest · Grand Rapids, Michigan
- Hackensack University Medical Center · Hackensack, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07164313 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify